OXFORD NANOPORE TECHNOLOGIES PLC ORD GBP0.0001OO

OXFORD NANOPORE TECHNOLOGIES PLC ORD GBP0.0001

121.2GBXD
+0.4+0.33%
At close at Jun 5, 16:37 GMT
GBX
No trades
See on Supercharts

ONT fundamentals

Key facts

Market capitalization‪1.16 B‬GBP
Basic EPS (TTM)−0.16GBP
Founded2005
Employees (FY)‪1.48 K‬
CEOGordon Sanghera
About

Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. It also develops instruments like GridIONTM and MinIONTM which are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. The firm's platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security and defense. The company was founded by Gordon Sanghera, Spike Willcocks and John Hagan Pryce Bayley in 2005 and is headquartered in Oxford, the United Kingdom.

Ownership
‪‪961.00 M‬‬
Closely held shares
‪‪668.29 M‬‬ (69.54%)
Free Float shares
‪‪292.71 M‬‬ (30.46%)
Closely held shares
‪‪668.29 M‬‬ (69.54%)
Free Float shares
‪‪292.71 M‬‬ (30.46%)
Capital structure
Market cap
‪‪1.16 B‬‬
Debt
‪‪45.96 M‬‬
Cash & equivalents
‪‪338.37 M‬‬
Enterprise value
‪‪868.48 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.16 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.19x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.19x
Valuation ratios
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−102%‬
‪−94%‬
‪−86%‬
‪−78%‬
‪−70%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−100.00 M‬‬
‪‪−50.00 M‬‬
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−100.00 M‬‬
‪‪−50.00 M‬‬
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−100.00 M‬‬
‪‪−50.00 M‬‬
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Deoxyribonucleic Acid and Ribonucleic Acid Sequencing Technology
Services
Lease
By country
Period: 2024
United States
Europe, Middle East, Africa, and India
APAC
United Kingdom
China
Germany
Americas
United Arab Emirates

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪26.00 M‬‬
‪‪52.00 M‬‬
‪‪78.00 M‬‬
‪‪104.00 M‬‬
Actual
Estimate
Earnings
Next:Sep 2, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪−0.10‬
‪−0.08‬
‪−0.05‬
‪−0.02‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
ONT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−120.00 M‬‬
‪0.00‬
‪‪120.00 M‬‬
‪‪240.00 M‬‬
‪‪360.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Assets
Liabilities